Latest Insider Transactions at Agios Pharmaceuticals, Inc. (AGIO)
This section provides a real-time view of insider transactions for Agios Pharmaceuticals, Inc. (AGIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AGIOS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AGIOS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2023
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,380
+50.0%
|
-
|
|
Jun 21
2023
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,975
+3.89%
|
-
|
|
Jun 21
2023
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,975
+29.14%
|
-
|
|
Jun 21
2023
|
Maykin Ho Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,975
+30.15%
|
-
|
|
Jun 21
2023
|
Kaye I Foster Cheek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,975
+30.15%
|
-
|
|
Apr 12
2023
|
Jacqualyn A Fouse Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,731
-4.8%
|
$99,351
$21.35 P/Share
|
|
Apr 08
2023
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,933
+13.92%
|
-
|
|
Apr 03
2023
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
16,363
-12.19%
|
$359,986
$22.85 P/Share
|
|
Apr 03
2023
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,363
+10.86%
|
$147,267
$9.05 P/Share
|
|
Mar 27
2023
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
20,000
-14.51%
|
$440,000
$22.15 P/Share
|
|
Mar 27
2023
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.67%
|
$180,000
$9.05 P/Share
|
|
Mar 13
2023
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
20,000
-7.35%
|
$440,000
$22.59 P/Share
|
|
Mar 13
2023
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.67%
|
$180,000
$9.05 P/Share
|
|
Mar 03
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
504
-15.53%
|
$12,096
$24.29 P/Share
|
|
Mar 03
2023
|
Sarah Gheuens Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,134
-5.34%
|
$28,350
$25.02 P/Share
|
|
Mar 03
2023
|
James William Burns Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,129
-4.12%
|
$28,225
$25.02 P/Share
|
|
Mar 01
2023
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,833
+15.28%
|
-
|
|
Mar 01
2023
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,833
+12.28%
|
-
|
|
Mar 01
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-7.76%
|
$6,825
$25.31 P/Share
|
|
Mar 01
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
777
+18.09%
|
-
|
|
Feb 27
2023
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
20,000
-14.51%
|
$500,000
$25.37 P/Share
|
|
Feb 27
2023
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.67%
|
$180,000
$9.05 P/Share
|
|
Feb 16
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
233
-8.03%
|
$6,291
$27.21 P/Share
|
|
Feb 16
2023
|
Jacqualyn A Fouse Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,648
-4.23%
|
$102,144
$28.91 P/Share
|
|
Feb 16
2023
|
James William Burns Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
609
-2.52%
|
$17,052
$28.91 P/Share
|
|
Feb 14
2023
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,333
+11.62%
|
-
|
|
Feb 14
2023
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,738
+6.71%
|
-
|
|
Feb 14
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
504
-14.8%
|
$14,112
$28.59 P/Share
|
|
Feb 14
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
400
-5.76%
|
$11,200
$28.68 P/Share
|
|
Feb 14
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
360
+9.25%
|
-
|
|
Feb 14
2023
|
Sarah Gheuens Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
758
-4.27%
|
$21,224
$28.44 P/Share
|
|
Feb 14
2023
|
James William Burns Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
643
-2.79%
|
$18,004
$28.44 P/Share
|
|
Feb 13
2023
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
20,000
-14.51%
|
$560,000
$28.62 P/Share
|
|
Feb 13
2023
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.67%
|
$180,000
$9.05 P/Share
|
|
Feb 10
2023
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,162
+10.85%
|
-
|
|
Feb 10
2023
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,834
+7.37%
|
-
|
|
Feb 10
2023
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
777
+18.4%
|
-
|
|
Jan 30
2023
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
20,000
-7.42%
|
$580,000
$29.55 P/Share
|
|
Jan 30
2023
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.67%
|
$180,000
$9.05 P/Share
|
|
Jan 17
2023
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
20,000
-7.31%
|
$580,000
$29.16 P/Share
|
|
Jan 17
2023
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.67%
|
$180,000
$9.05 P/Share
|
|
Jan 13
2023
|
Kaye I Foster Cheek Director |
SELL
Bona fide gift
|
Direct |
2,200
-25.15%
|
-
|
|
Dec 28
2022
|
Sarah Gheuens Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,783
-15.13%
|
$77,924
$28.48 P/Share
|
|
Dec 28
2022
|
James William Burns Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,597
-10.9%
|
$72,716
$28.48 P/Share
|
|
Dec 23
2022
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+33.77%
|
-
|
|
Dec 23
2022
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+26.87%
|
-
|
|
Dec 06
2022
|
Sarah Gheuens Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
248
-2.68%
|
$6,944
$28.83 P/Share
|
|
Dec 02
2022
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
833
+8.25%
|
-
|
|
Oct 17
2022
|
Richa Poddar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,485
-14.86%
|
$40,095
$27.48 P/Share
|
|
Oct 15
2022
|
Richa Poddar Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+33.35%
|
-
|